Studies have shown altered levels of KP metabolites in the cerebrospinal fluid (CSF) and blood of AD patients, indicating the pathway’s involvement in the disease’s pathogenesis (Si et al. 2023). This evidence concerns the gene NPPA and Alzheimer disease.